Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 100
Filter
Add more filters

Country/Region as subject
Affiliation country
Publication year range
1.
Breast Cancer Res Treat ; 165(2): 261-271, 2017 Sep.
Article in English | MEDLINE | ID: mdl-28578507

ABSTRACT

PURPOSE: To report our experience with full-dose 21 Gy IORT in early breast cancer patients after breast-conserving surgery to define most important selection factors. METHODS: Seven hundred and fifty eight patients, subjected to conserving surgery and IORT, were retrospectively analyzed evaluating most important clinical outcomes. RESULTS: Median follow up was 5.2 years. Results from Cox analyses defined 2 groups of patients, "suitable" (age > 50 years, non lobular histology, tumour size ≤ 2 cm, pN0 or pNmic, ki67 ≤ 20%, non triple negative receptor status and G1-G2) and "unsuitable" for IORT, with a higher rate of breast related events moving from "suitable" to "unsuitable" group. The 5 year rate of IBR is 1.8% in suitable group with significant differences versus unsuitable (1.8 vs. 11.6%, p < 0.005). Same differences between two groups were evidenced in true local relapse (0.6 vs. 6.9%, p < 0.005) and in new ipsilateral BC (1.1 vs. 4.7%, p < 0.015). CONCLUSIONS: In our current practice we consider the following preoperative factors to select patients suitable for IORT: age > 50 years, absence of lobular histology, tumor size ≤ 2 cm, pN0 or pNmic, according to APBI consensus statement, including also ki67 ≤ 20%, non triple negative receptor status and G1-G2.


Subject(s)
Breast Neoplasms/radiotherapy , Electrons , Intraoperative Care , Radiotherapy/methods , Breast Neoplasms/diagnosis , Breast Neoplasms/mortality , Breast Neoplasms/surgery , Combined Modality Therapy , Female , Humans , Intraoperative Care/methods , Neoplasm Grading , Neoplasm Staging , Preoperative Care , Prognosis , Retrospective Studies , Treatment Outcome , Tumor Burden
2.
J Neurol Neurosurg Psychiatry ; 81(7): 731-3, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20581138

ABSTRACT

BACKGROUND: It has been recently observed that small fibre neuropathy (SFN) may present as distal symmetrical polyneuropathy and with atypical non-length-dependent pattern. OBJECTIVE: To describe a small series of patients with non-length-dependent SFN, investigating corneal innervation with corneal confocal microscopy (CCM). METHODS: Evaluation of the corneal nerve fibre density using CCM in six women with non-length-dependent SFN. The patients were characterised by sensory disturbance involving proximal regions of the limbs, face and trunks, and the diagnosis was confirmed by the findings of decreased intraepidermal nerve fibre density on skin biopsy. RESULTS: Six women, aged 35-64, had non-length-dependent SFN, related to Crohn disease, impaired glucose tolerance and Sjögren's syndrome, or idiopathic (three cases). In all patients, CCM demonstrated decreased corneal nerve fibre density (12.5-23.4/mm(2); normal, >30.6/mm(2)). CONCLUSION: Non-length-dependent SFN may represent an intriguing diagnostic problem because of its puzzling presentation and the need for special investigations for its confirmation. In this perspective, CCM may provide a useful, non-invasive tool to complement the diagnostic workup.


Subject(s)
Cornea/innervation , Cornea/pathology , Microscopy, Confocal/methods , Nerve Fibers/pathology , Peripheral Nervous System Diseases/pathology , Adult , Amines/therapeutic use , Amitriptyline/therapeutic use , Analgesics/therapeutic use , Antidepressive Agents, Second-Generation/therapeutic use , Antidepressive Agents, Tricyclic/therapeutic use , Biopsy , Crohn Disease/complications , Crohn Disease/pathology , Cyclohexanecarboxylic Acids/therapeutic use , Duloxetine Hydrochloride , Electrophysiology , Female , Gabapentin , Humans , Middle Aged , Nerve Endings/pathology , Nerve Endings/ultrastructure , Peripheral Nervous System Diseases/drug therapy , Sensation Disorders/complications , Sensation Disorders/pathology , Sjogren's Syndrome/complications , Sjogren's Syndrome/pathology , Skin/innervation , Skin/pathology , Thiophenes/therapeutic use , Trigeminal Nerve/pathology , Trigeminal Nerve/ultrastructure , gamma-Aminobutyric Acid/therapeutic use
3.
Transplant Proc ; 40(5): 1763-7, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18589190

ABSTRACT

An 11-year-old boy with irreversible intestinal failure secondary to chronic intestinal pseudo-obstruction (CIPO) and intestinal failure-associated liver disease (IFALD) underwent a combined en bloc reduced liver and small bowel transplantation. He was discharged home after 9 weeks on full oral intake without requiring intravenous nutritional or fluid supplementation. The first episode of mild acute rejection, which occurred 18 months after transplantation, was successfully treated with steroids. An episode of rotavirus gastroenteritis led to severe exfoliative rejection of the bowel graft, which was resistant to steroid and Infliximab treatment but responded to OKT3. There was associated Epstein-Barr virus viremia with no evidence of posttransplant lymphoproliferative disease. Another episode of moderate to severe acute liver rejection occurred 5 months later. At the same time, multiple biliary strictures were diagnosed and treated. Persistent clinical symptoms of abdominal pain and increased stomal output as well as atrophy of the ileal mucosa on several biopsies, suggested the possibility of chronic rejection (CR). A second combined whole liver and small bowel transplant was performed. The diagnosis of CR was confirmed on histology of the explanted graft. The postoperative course was severely complicated and 71 days after the retransplantation, the boy died because of respiratory failure and multiorgan failure. In summary, intestinal transplantation can be successfully performed in children with CIPO, giving them the opportunity to be free from total parenteral nutrition. As survival following intestinal transplantation continues to improve, the problem of CR has become increasingly important and the only treatment available is retransplantation, which is associated with poor outcomes.


Subject(s)
Graft Rejection/drug therapy , Intestinal Pseudo-Obstruction/surgery , Intestine, Small/transplantation , Liver Transplantation , Adrenal Cortex Hormones/therapeutic use , Child , Chronic Disease , Colon/transplantation , Fatal Outcome , Humans , Immunosuppressive Agents/therapeutic use , Liver Transplantation/adverse effects , Male , Multiple Organ Failure , Pancreas Transplantation/adverse effects , Reoperation
4.
Acta Neurochir (Wien) ; 150(9): 879-86; discussion 887, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18754072

ABSTRACT

INTRODUCTION: The risk of leaving a remnant after surgery for a cavernous malformation in the brainstem is generally not stressed enough, even though such remnants appear to have a high risk of re-bleeding. At least 40% of known cavernoma remnants after surgery have further bleeding episodes. A retrospective analysis of 30 patients with brainstem cavernoma who underwent surgery is presented, focusing on incidence, risk factors and management of post-surgical residuals. The sites were, medulla in three patients, pons-medulla in four, pons in 16, pons-midbrain in four and midbrain in three. All 30 patients came to our clinical observation with at least one episode of acute-onset neurological deficit and all were operated in the sub-acute phase. Only one patient had a worse stable outcome than the pre-surgical state, and 29 did better or were stable. All patients had a brain MRI scan within 72 h after surgery to confirm that complete removal had been achieved. In three, although the surgical cavity and its border appeared clean at the end of surgery, with no lesion remaining, post-operative MRI detected a residuum. These three patients were re-operated, but one had a further bleed prior to excision. MATERIALS AND METHODS: In our series, the surgical finding of a multi-lobular cavernoma (as opposed to the more frequent finding of a discrete lesion with a thick capsule), with a thin wall and satellite nodules separated by a thin layer of apparently intact white matter, was common (seven patients). This group included the three patients with evidence of residuum on post-operative MRI. In our experience, the surgical finding of a multi-lobular cavernoma carries a higher risk of residuum and post-surgical re-bleeding. CONCLUSION: Immediate post-operative brain MRI scans are therefore strongly recommended for their detection, especially in this group of patients, and if a residual is detected early re-intervention is less risky than the natural history.


Subject(s)
Brain Stem Neoplasms/surgery , Hemangioma, Cavernous, Central Nervous System/surgery , Neurosurgical Procedures , Adolescent , Adult , Brain Stem Neoplasms/pathology , Child , Child, Preschool , Hemangioma, Cavernous, Central Nervous System/pathology , Humans , Incidence , Magnetic Resonance Imaging , Middle Aged , Neoplasm, Residual/diagnosis , Neoplasm, Residual/epidemiology , Neoplasm, Residual/surgery , Postoperative Period , Reoperation , Risk Factors , Time Factors , Treatment Outcome , Young Adult
5.
Mol Endocrinol ; 10(3): 272-85, 1996 Mar.
Article in English | MEDLINE | ID: mdl-8833656

ABSTRACT

Two different human prolactinoma phenotypes (responders and nonresponders), which are distinguished by different tumorigenic potential and different responsiveness to dopaminergic therapy, have recently been identified. Responders show low proliferation rate, low tumorigenic potential, and expression of D-2 receptors for dopamine (DA), while nonresponders are characterized by high proliferation rate, high tumorigenic potential, and lack of expression of DA D-2 receptors. In this study it has been shown that both gp140trk and gp75 components of nerve growth factor (NGF) receptor are expressed in responder prolactinoma cell lines. High levels of both NGF gene transcript and protein were also found in responders, and biologically active NGF was detectable in the media conditioned by these cells. Ablation of NGF production in responder cells by hybridization arrest of translation through NGF antisense oligonucleotides resulted in: 1) loss of secreted NGF; 2) loss of expression of gp75; 3) loss of expression of DA D-2 receptors; and 4) a remarkable increase in the cell proliferation rate. These results thus suggest that a NGF-mediated autocrine loop essential to control cell proliferation and to preserve some phenotypical characteristics of mammotroph cells is present in responder prolactinoma cell lines. Analysis of nonresponders showed that these cells express gp140trk but no detectable levels of gp75. In addition, no NGF mRNA or protein was detectable in nonresponders. Exposure of these cells to NGF resulted in the permanent expression of NGF mRNA and in the production and secretion of NGF protein, thus establishing the same NGF-mediated autocrine loop present in responders. As a result, it has been shown that nonresponder cells treated with NGF acquire and maintain most of the phenotypic characteristics of normal mammotroph cells. In conclusion, the present work reports that a NGF-mediated autocrine loop with an inhibitory role in the control of cell proliferation and tumor progression is active in the more differentiated DA-sensitive prolactinoma cell lines and is lost in the most malignant prolactinoma cells refractory to the dopaminergic therapy. Alterations in the expression of this autocrine loop thus may lead to cell transformation and tumor progression.


Subject(s)
Neoplasm Proteins/physiology , Nerve Growth Factors/physiology , Pituitary Neoplasms/pathology , Prolactinoma/pathology , Proto-Oncogene Proteins/physiology , Receptor Protein-Tyrosine Kinases/physiology , Receptors, Nerve Growth Factor/physiology , Animals , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Bromocriptine/pharmacology , Bromocriptine/therapeutic use , Cell Division/drug effects , Dopamine Agents/pharmacology , Dopamine Agents/therapeutic use , Drug Resistance, Neoplasm , Gene Expression Regulation, Neoplastic/drug effects , Humans , Mice , Mice, Nude , Neoplasm Proteins/antagonists & inhibitors , Neoplasm Proteins/biosynthesis , Neoplasm Proteins/genetics , Neoplasm Transplantation , Nerve Growth Factors/antagonists & inhibitors , Nerve Growth Factors/biosynthesis , Nerve Growth Factors/genetics , Nerve Growth Factors/pharmacology , Oligonucleotides, Antisense/pharmacology , Pituitary Neoplasms/classification , Pituitary Neoplasms/drug therapy , Pituitary Neoplasms/metabolism , Prolactinoma/classification , Prolactinoma/drug therapy , Prolactinoma/metabolism , Proto-Oncogene Proteins/drug effects , Receptor Protein-Tyrosine Kinases/drug effects , Receptor, Nerve Growth Factor , Receptor, trkA , Receptors, Dopamine D2/biosynthesis , Receptors, Dopamine D2/genetics , Receptors, Nerve Growth Factor/drug effects , Tumor Cells, Cultured/drug effects
6.
Transplant Proc ; 37(2): 1146-8, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15848651

ABSTRACT

We reviewed the clinical data of 30 children-hospitalized for acute liver failure in the last 6 years. Ten patients were not listed for liver transplantation OLTX. Their clinical conditions gradually improved and they are all alive without deficit. Among 20 patients listed, 15 underwent urgent OLTX. Two children died on the waiting list and three were suspended from waiting list after few days because of improvement. Survival according to age class was analyzed dividing the patients into two groups: A, age 1 year or less versus B, age between 1 and 16 years. The patient survival was 86% at 6 months and 61% both at 1 and 2 years. Survival at 6 months and 1 and 2 years was 88%, 67%, and 45% for the patients in group A and 83%, 83%, and 83% for the patients in group B (P = NS). Observing graft-to-recipient weight ratio and donor-to-recipient weight ratio most patients received an optimal sized graft. The split-liver technique is considered the preferred method of liver transplantation even in the pediatric patients with acute liver failure; especially in the setting of a cooperative system in which all livers that are suitable for split-liver transplantation are shared between centers. In order to have the best chance for survival, children with acute liver failure should be referred as soon as possible to an highly specialized pediatric liver transplantation center that can offer all the treatment modalities that are currently available.


Subject(s)
Liver Failure, Acute/surgery , Adolescent , Child , Child, Preschool , Humans , Infant , Infant, Newborn , Italy , Liver Diseases/mortality , Liver Diseases/surgery , Retrospective Studies , Treatment Outcome , Waiting Lists
7.
Transplant Proc ; 37(2): 1149-50, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15848652

ABSTRACT

In this study we analyzed the features of 12 patients who underwent liver transplantation for progressive familial intrahepatic cholestasis (Byler's disease [BD]) in view of the technical features of the OLTx, incidence and type of complications, need for retransplantation, as well as patient and graft survivals. BD was the indication in 12 patients of median age 1.32 years and median weight 10 kg. Median follow-up was 670 days. Major surgical complications requiring reintervention occurred in three patients. No thrombosis of the hepatic artery was observed. Infections with positive blood cultures were diagnosed in four patients. One patient had a biliary anastomotic stenosis successfully treated by percutaneous techniques. Four patients had episodes of acute rejection treated with steroids. Two patients were retransplanted, both of whom died in the early postoperative period due to hepatic vein thrombosis and venoenteric fistula. The actuarial patient and graft survival was 83% at 1 year and 83% at 5 years. Split-liver grafts represent an excellent organ supply for these patients, achieving good results with no mortality on the waiting list.


Subject(s)
Liver Cirrhosis, Biliary/surgery , Liver Transplantation , Adolescent , Child , Child, Preschool , Female , Follow-Up Studies , Humans , Infant , Male , Retrospective Studies , Treatment Outcome
8.
Transplant Proc ; 37(2): 1153-4, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15848654

ABSTRACT

Biliary atresia (BA) represents the most frequent indication for liver transplantation (OLTX) in the pediatric population. The aim of this paper was to present a series collected over the last 7 years from October 1997 through July 2004, including 260 pediatric OLTX in 231 patients. BA was the indication in 137 patients. There were 69 boys and 68 girls of mean weight 10.68 kg and median age 0.9 years. As a primary transplant, 99 patients received a LLS graft; 27 a whole graft; four a I+IV-VIII segment, and two a I-IV segment. Mean follow up was 1047 days (range, 1-2496 day). Infections were diagnosed in 45 patients, vascular complications in 27 patients. Surgical complications that required reintervention occurred in 25 patients. In 41 cases biliary complications occurred, 11 requiring reintervention. 16 patients were retransplanted. In two cases another re-OLTx was performed. Currently 126 patients are alive, showing an actuarial 1 year survival of 92% and 5 year 91%, with actuarial graft survivals of 85% at 1 year and 82% at 3 and 5 years. Our results confirm the effectiveness of OLTx for the treatment of children with BA and a failed Kasai procedure. Split liver grafts represent an excellent organ supply for these patients, achieving optimal results with no mortality on the waiting list.


Subject(s)
Biliary Atresia/surgery , Liver Transplantation , ABO Blood-Group System , Adolescent , Blood Group Incompatibility , Child , Child, Preschool , Female , Graft Survival , Humans , Infant , Intraoperative Complications/epidemiology , Liver Transplantation/immunology , Liver Transplantation/methods , Liver Transplantation/mortality , Male , Postoperative Complications/epidemiology , Reoperation/statistics & numerical data , Retrospective Studies , Survival Analysis
9.
Transplant Proc ; 37(2): 1174-6, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15848660

ABSTRACT

Alagille syndrome (AS) is a dominantly inherited, multisystem disorder involving the liver, heart, eyes, face, and skeleton. From October 1997 through July 2004, 260 pediatric orthotopic liver transplantations (OLTx) were performed in 231 patients. This report describes 21 patients of median age 1.95 years (range, 0.7-16.7) who had alagille syndrome. We present the technical features of the OLTx, incidence and type of complications, medical conditions related to the syndrome, need for retransplantation, as well as patient and graft survival rates. A split liver technique was used in 16 patients (76%) who received a left lateral segment (LLS) graft whereas 7 patients (33%) received a whole liver. Only cadaveric donors were used. The major surgical complications requiring reintervention in 11 patients (52%) included biliary problems (19%) and vascular complications (17%). One case of hepatic artery thrombosis required retransplantation. Three recipients (14%) died. All other patients are alive with an actuarial survival rate of 90% at 1 year and 80% at 5 years. The actuarial graft survival rate is 85% at 1 year and 75% at 5 years. Patients with AS, despite the associated cardiovascular anomalies, can be treated successfully by a combined approach between cardiologist, radiologist, cardiothoracic, and liver transplant surgeons. With careful planning and operative management, the results are comparable with those obtained with other more common cholestatic diseases.


Subject(s)
Alagille Syndrome/surgery , Liver Transplantation/statistics & numerical data , Actuarial Analysis , Cardiac Catheterization , Child , Follow-Up Studies , Humans , Liver Transplantation/mortality , Postoperative Complications/classification , Postoperative Complications/epidemiology , Retrospective Studies , Survival Analysis , Time Factors
10.
J Clin Endocrinol Metab ; 81(8): 3084-90, 1996 Aug.
Article in English | MEDLINE | ID: mdl-8768879

ABSTRACT

The recorded number of patients with central hyperthyroidism due to TSH-secreting pituitary adenoma doubled in the last few years after the introduction of ultrasensitive TSH assays in the assessment of thyroid function; however, information about the results and the criteria for cure after pituitary surgery is scanty. Seventeen patients with a TSH-secreting adenoma, diagnosed on the basis of detectable TSH levels in the face of high free thyroid hormone concentrations and pituitary lesion at neuroimaging, underwent pituitary surgery. Hypersecretion of other pituitary hormones was diagnosed in 5 of 17 patients. Four patients were initially misdiagnosed and treated with thyroid surgery or radioiodine therapy. The majority (86%) of hyperthyroid patients normalized thyroid hormone concentrations and regained euthyroidism, although pituitary imaging, alpha-subunit, and alpha-subunit/TSH molar ratio normalized in only 47%, 54%, and 58% of patients, respectively. Moreover, TSH secretion was normally suppressed by T3 in 40% of the patients. Interestingly, the finding of undetectable TSH levels 7 days after surgery was highly predictive of successful outcome. During long term follow-up, there was one relapse of hyperthyroidism. Early diagnosis of TSH-secreting adenomas permits a high rate of remission of hyperthyroidism after surgery. However, normalization of thyroid function alone does not necessarily reflect complete removal of the tumor, and more comprehensive criteria of cure based on pituitary imaging, hormone measurement, and suppression of TSH during T3 administration should be used. Lastly, all patients need an accurate long term follow-up to monitor the possible recurrence of the adenoma.


Subject(s)
Adenoma/complications , Adenoma/metabolism , Hyperthyroidism/etiology , Hyperthyroidism/surgery , Pituitary Neoplasms/complications , Pituitary Neoplasms/metabolism , Thyrotropin/metabolism , Adenoma/surgery , Adult , Endocrine Glands/physiopathology , Female , Follow-Up Studies , Humans , Male , Middle Aged , Pituitary Neoplasms/surgery , Postoperative Period , Remission Induction , Thyroid Hormones/blood , Thyrotropin/blood
11.
J Clin Endocrinol Metab ; 86(11): 5194-200, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11701676

ABSTRACT

To investigate the effects of octreotide administration on the growth rate of GH-secreting pituitary adenomas, we measured both the Ki-67 labeling index (LI) and the apoptotic index in tumor specimens from octreotide-treated or matched untreated acromegalic patients. Thirty-nine patients who received octreotide until the day of or the day before surgery and 39 untreated patients matched for sex, age, tumor size, extension, and invasiveness were studied. Immunocytochemical analysis was performed on paraffin-embedded material using a monoclonal antibody (MIB-1) directed against a proliferation-associated nuclear antigen, Ki-67, to measure the growth fraction. Apoptosis was assessed by the terminal deoxynucleotidyl transferase-mediated deoxy-UTP nick endlabeling method, using a monoclonal antibody recognizing areas of DNA fragmentation. The Ki-67 LI and apoptosis were counted on separate slides in at least 1000 evaluable cells. Octreotide-treated patients showed a lower Ki-67 LI (1.8 +/- 0.3%) than untreated controls (3.8 +/- 0.7%; P < 0.02). Overall, the mean Ki-67 LI of treated patients was 53% lower than that in untreated patients. The antiproliferative effect of octreotide occurred independently of tumor extension and invasiveness. Octreotide-treated and untreated patients showed similar apoptotic indexes (0.6 +/- 0.2% and 0.8 +/- 0.3%, respectively). There was a positive correlation between the Ki-67 LI and the apoptotic index (r = 0.29; P < 0.03). Our study demonstrates that acromegalic patients receiving chronic octreotide treatment have a lower value of the proliferation marker Ki-67, but no significant difference in the apoptotic index compared with matched untreated patients. The antiproliferative effect of octreotide on GH-secreting adenomas should imply a lower risk of tumor growth during long-term chronic treatment with the drug.


Subject(s)
Adenoma/metabolism , Apoptosis/drug effects , Hormones/therapeutic use , Human Growth Hormone/biosynthesis , Octreotide/therapeutic use , Pituitary Neoplasms/metabolism , Acromegaly/pathology , Adenoma/pathology , Adult , Antibodies, Monoclonal/pharmacology , Cell Division , Female , Humans , Immunohistochemistry , In Situ Nick-End Labeling , Ki-67 Antigen , Male , Pituitary Neoplasms/pathology , Tissue Embedding
12.
Metabolism ; 45(8 Suppl 1): 115-6, 1996 Aug.
Article in English | MEDLINE | ID: mdl-8769402

ABSTRACT

In a series of approximately 1,000 patients with pituitary adenoma who were operated on at our institution from 1970 to 1994, 932 were operated on for the first time. Most microadenomas were corticotropin (ACTH)-secreting, whereas all nonfunctioning adenomas were macroadenomas, reflecting internal surgical policy. Only 48 of 932 patients (5.1%) had transcranial surgery. Using stringent criteria for the definition of a cure, we obtained remission of disease in 54.9%, 87.3%, 66.7%, and 46.2% of all patients with growth hormone (GH)-, ACTH-, thyrotropin (TSH)-, and prolactin (PRL)-secreting adenomas, respectively. The good result in patients with Cushing's disease is related to the higher percentage of microadenomas (approximately equal to 80%) in this group. Unfavorable prognostic characteristics for all adenomas are increasing tumor size, invasiveness, infiltration, and high serum levels of the hypersecreted hormone. The absence of a reliable tumor marker makes it difficult to assess the results of surgery in patients with nonfunctioning pituitary adenoma, but normalization or improvement of visual defects occurred in 72.4% of patients. Permanent worsening of vision was detected in 2.2%, mostly operated on through the transcranial approach, but they had large tumors and so were at greater risk. Accordingly, there was a higher death rate in patients who received the transcranial operation (two of 48; 4.2%) than in patients operated on through the trans-sphenoidal route (seven of 884; 0.8%). However, between 1970 and 1980, the mortality rate was 1.6% (six of 367 patients), while between 1981 and 1994, it was 0.5% (three of 565 patients), stressing the importance of surgical experience and perioperative medical management in improving the safety of pituitary surgery.


Subject(s)
Adenoma/surgery , Pituitary Neoplasms/surgery , Humans , Postoperative Complications , Treatment Outcome
13.
Neurosurgery ; 47(6): 1313-8; discussion 1318-9, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11126902

ABSTRACT

OBJECTIVE: The recurrence of nonfunctioning pituitary adenomas (NFPAs) after surgical removal is common. The aim of our study was to investigate and correlate the growth fraction of NFPAs with clinical characteristics and long-term follow-up results. METHODS: Tumor specimens were obtained from 101 consecutive patients with NFPAs (48 female patients and 53 male patients; mean age, 52.0 +/- 1.5 yr). Specimens were immediately fixed in 10% buffered formalin and then embedded in paraffin. The Ki-67 antigen was assessed by immunocytochemical analysis using the monoclonal antibody MIB-1. The Ki-67 antigen labeling index (LI) was determined by counting a total of at least 1,000 neoplastic nuclei. RESULTS: The mean Ki-67 LI for the 101 patients was 2.4 +/- 0.3% (range, 0-23.0%). Only age at surgery was inversely correlated with the Ki-67 LI; sex, maximal tumor diameter, and invasiveness into the cavernous sinuses did not significantly affect the Ki-67 LI. The mean follow-up period was 39.7 +/- 2.1 months. During follow-up monitoring, 23 patients experienced tumor recurrence, after a mean period of 28.6 +/- 4.8 months. Invasiveness of the tumor on preoperative magnetic resonance imaging scans was the strongest predictor of late tumor recurrence, followed by previous pituitary surgery, younger age, and lack of postoperative radiotherapy. The Ki-67 LI had no independent prognostic value. CONCLUSION: Our study suggests that the clinical characteristics of patients with NFPAs, except for age at surgery, are not correlated with the Ki-67 LI. Moreover, the Ki-67 LI does not seem to provide independent information to identify patients at high risk for tumor recurrence.


Subject(s)
Adenoma/pathology , Pituitary Neoplasms/pathology , Adenoma/diagnosis , Adenoma/immunology , Cell Division , Female , Follow-Up Studies , Humans , Ki-67 Antigen/analysis , Magnetic Resonance Imaging , Male , Middle Aged , Neoplasm Invasiveness/pathology , Neoplasm Recurrence, Local , Pituitary Neoplasms/diagnosis , Pituitary Neoplasms/immunology , Prognosis
14.
J Neurosurg ; 93(1): 121-6, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10883914

ABSTRACT

Acromegaly is usually caused by a growth hormone (GH)-secreting pituitary adenoma, and hypersecretion of GH-releasing hormone (GHRH) from a hypothalamic or neuroendocrine tumor accounts for other cases. The authors report on the unusual association of acromegaly with a granular cell tumor of the neurohypophysis. A 42-year-old woman with a 10-year history of acral enlargement, headache, and menstrual abnormalities was referred to our department for a suspected GH-secreting pituitary adenoma. The patient's basal GH levels were mildly elevated at 4.8 microg/L, were not suppressed in response to an oral glucose tolerance test, and increased paradoxically after administration of thyrotropin-releasing hormone. The patient's insulin-like growth factor-1 (IGF-1) level was elevated at 462 microg/L, whereas a magnetic resonance image of the sella turcica revealed an intra- and suprasellar lesion that was compatible with a diagnosis of pituitary adenoma. A transsphenoidal approach to remove the lesion, which was mainly suprasellar, was successful during a second operative attempt, resulting in the clinical and biochemical regression of the patient's acromegaly. Four months postoperatively, the patient's basal GH level was 0.9 microg/L and her IGF-1 level was 140 microg/L. Histological analysis of the operative specimen demonstrated a granular cell tumor of the neurohypophysis, which when stained proved negative for pituitary hormones and GHRH. This case represents the first reported association between a granular cell tumor of the neurohypophysis and acromegaly. Granular cell tumor of the neurohypophysis could be added to the restricted list of neoplastic causes of acromegaly secondary to hypersecretion of a GH-releasing substance.


Subject(s)
Acromegaly/pathology , Granular Cell Tumor/pathology , Pituitary Gland, Posterior/pathology , Pituitary Neoplasms/pathology , Adult , Diagnosis, Differential , Female , Growth Hormone-Releasing Hormone/analysis , Humans , Immunoenzyme Techniques , Magnetic Resonance Imaging , Microscopy, Electron
15.
J Neurosurg ; 44(6): 677-86, 1976 Jun.
Article in English | MEDLINE | ID: mdl-818343

ABSTRACT

The preoperative outlook and surgical results are evaluated in 29 acromegalic patients, employing the usual serum growth hormone (GH) screening techniques in association with GH response to the thyrotropin releasing hormone (TRH) test. Results obtained by transsphenoidal microsurgical technique in adenomas of different size and sellar morphology are reported. Overall results clearly favor selective microsurgery in early diagnosed and operated tumors (microadenomas), while a less than radical approach does not hold much promise of functional normalization in larger adenomas. In nonnormalized cases the efficacy of radiotherapy is stressed. The TRH test results were a good indication for radiation therapy even in those cases in which GH normalized after surgery by common assay methods.


Subject(s)
Acromegaly/surgery , Microsurgery/methods , Acromegaly/blood , Adenoma/surgery , Adult , Aged , Female , Growth Hormone/blood , Humans , Insulin/pharmacology , Male , Middle Aged , Pituitary Neoplasms/surgery , Thyrotropin-Releasing Hormone/pharmacology
16.
J Neurosurg ; 59(3): 402-8, 1983 Sep.
Article in English | MEDLINE | ID: mdl-6411870

ABSTRACT

The criteria by which acromegalic patients are considered "cured" after surgical therapy are still controversial. Since the abnormal growth hormone (GH) increase after the administration of some agents has been demonstrated to be characteristic of the tumoral somatotrophs, its disappearance after surgery may be taken as an index of the complete removal of the tumor. Serum GH increases after thyrotropin-releasing hormone (TRH, 200 micrograms intravenously), gonadotropin-releasing hormone (Gn-RH, 100 micrograms intravenously), and sulpiride (100 mg intramuscularly) injected during dopamine infusion (DA-Slp test), were evaluated in 68 acromegalic patients before and after transnasosphenoidal adenomectomy, and every 12 to 18 months during a follow-up period of 6 months to 11 years (average 42 months). Forty-two patients had abnormal responses to at least one test before surgery: 32 out of 68 (47%) to TRH, six out of 40 (15%) to Gn-RH, and 20 out of 28 (71%) to the DA-Slp test. Of 18 patients who underwent all three tests, 78% had abnormal responses to at least one of them. Twenty-three patients became unresponsive after surgery, and none of them had a recurrence or became abnormally responsive again during the follow-up period. Three out of six patients with postoperative serum GH levels between 5.1 and 10 ng/ml and three out of six patients with postoperative serum GH levels between 2.1 and 5 ng/ml remained abnormally responsive: one of them relapsed 1 year after the operation. The abnormal responses were lost in all 11 patients whose postoperative serum GH levels were below 2 ng/ml, and abnormal responses were maintained in all the patients in whom surgery was considered unsuccessful because postoperative serum GH levels were higher than 10 ng/ml. The TRH, Gn-RH, and DA-Slp tests should thus be considered useful tools in verifying the total removal of an adenoma. The reappearance of active acromegaly in the patient with low postoperative GH levels, who was still responsive to TRH, should be regarded as a reactivation and not a true recurrence of the disease.


Subject(s)
Acromegaly/surgery , Adult , Aged , Dopamine , Female , Follow-Up Studies , Growth Hormone/blood , Humans , Male , Middle Aged , Outcome and Process Assessment, Health Care , Pituitary Hormone-Releasing Hormones , Sulpiride , Thyrotropin-Releasing Hormone
17.
Minerva Endocrinol ; 28(1): 39-51, 2003 Mar.
Article in Italian | MEDLINE | ID: mdl-12621362

ABSTRACT

Somatostatin analogues are widely employed in the treatment of hypophyseal adenomas. The most widely used analogues at the present time are octreotide and lanreotide. Both are available in slow release formulations using the parenteral route and show a preferential affinity for the sst(2) receptor of somatostatin. Both octreotide and lanreotide have proved their effectiveness in the treatment of GH- and TSH-secretory hypophyseal adenomas. In those patients who respond to pharmacological treatment we often achieve not only the control of hormonal hypersecretion, but also a reduction in the volume of hypophyseal neoplasia. In the other types of hypophyseal adenoma, on the other hand, somatostatin analogues have proved to have little effect: apart from isolated cases of effectiveness in non-functioning adenomas, the administration both of octreotide and lanreotide to patients with Cushing's disease or prolactinoma did not significantly modify the hormonal hypersecretion or tumoural volume. The side-effects of somatostatin analogues are comparatively rare and of moderate entity: only a small percentage of patients requires the treatment to be suspended owing to the occurrence of side-effects. New analogues are currently under study. These have a different receptor profile and they could therefore find new applications in hypophyseal pathology. Octreotide, bound to radioactive substances or to toxins, has also been utilised for the selective destruction of neoplastic tissues expressing the sst(2) receptor of somatostatin.


Subject(s)
Adenoma/drug therapy , Antineoplastic Agents, Hormonal/therapeutic use , Pituitary Neoplasms/drug therapy , Somatostatin/analogs & derivatives , Acromegaly/drug therapy , Acromegaly/etiology , Adenoma/complications , Adenoma/metabolism , Adenoma/radiotherapy , Adrenocorticotropic Hormone/metabolism , Antineoplastic Agents, Hormonal/adverse effects , Antineoplastic Agents, Hormonal/pharmacology , Combined Modality Therapy , Cushing Syndrome/drug therapy , Cushing Syndrome/etiology , Forecasting , Human Growth Hormone/metabolism , Humans , Insulin-Like Growth Factor I/metabolism , Octreotide/adverse effects , Octreotide/pharmacology , Octreotide/therapeutic use , Peptides, Cyclic/adverse effects , Peptides, Cyclic/pharmacology , Peptides, Cyclic/therapeutic use , Pituitary Neoplasms/complications , Pituitary Neoplasms/metabolism , Pituitary Neoplasms/radiotherapy , Prolactinoma/drug therapy , Radiopharmaceuticals/therapeutic use , Receptors, Somatostatin/drug effects , Receptors, Somatostatin/physiology , Somatostatin/adverse effects , Somatostatin/pharmacology , Somatostatin/therapeutic use , Thyrotropin/metabolism , Treatment Outcome , Yttrium Radioisotopes/therapeutic use
18.
J Neurosurg Sci ; 44(2): 89-93, 2000 Jun.
Article in English | MEDLINE | ID: mdl-11105837

ABSTRACT

Symptomatic glial cyst of the pineal gland are rare lesions. Origin, natural history and factors leading to cyst enlargement are not completely clear; thus management remain uncertain in some cases. We report a case of symptomatic glial cyst and analyze the implication for surgery. Surgical management is indicated in patients presenting hydrocephalus, mass effect or symptoms related to mesencephalic dysfunction. The infratentorial supracerebellar approach represent the first choice for this condition allowing easy orientation with wide exposure of the tumor and good visibility of deep venous systems that may be preserved. Size of the tumor is a key element in evaluation of the treatment and the appropriate course for asymptomatic cyst less than 1 cm in size consist of conservative management. Periodic follow up is always indicated.


Subject(s)
Brain Diseases/surgery , Cysts/surgery , Pineal Gland , Adult , Brain Diseases/diagnostic imaging , Brain Diseases/pathology , Cysts/diagnostic imaging , Cysts/pathology , Female , Humans , Hydrocephalus/etiology , Mesencephalon , Tomography, X-Ray Computed , Treatment Outcome
19.
J Neurosurg Sci ; 44(2): 103-6, 2000 Jun.
Article in English | MEDLINE | ID: mdl-11105840

ABSTRACT

Occurrence of internal carotid artery injuries associated with skull base fracture has been reported. A. report a case of fatal intracranial carotid dissection related to petrous fracture involving the carotid canal. Identification of carotid lesions may be difficult and generally related to appearance of unexpected neurological deficit. Skull base fractures may be considered an indirect sign for detection of vascular injury. Patterns of the fracture are of paramount importance; routine CT scan may fail to detect basilar fractures and high definition fine-cut CT scan should be executed to carefully identify and evaluate fractures. Temporal and sphenoid bone fractures are common in head trauma and involvement of the course of the carotid artery is frequent. The involvement of the intracranial carotid artery course represents a direct risk factor for lesions of the petrous, lacerum and cavernous segments of the carotid artery. Early diagnosis of post-traumatic vascular injury may lead to prognosis improvement because of effectiveness of heparin anticoagulant therapy. Then vascular screening is recommendable in cases with complex fractures of the skull base and particularly fracturing along the course of the carotid artery. Magnetic resonance angiography may be considered the first line diagnostic tools for vascular screening. Angiography may be reserved for patients with a proven lesion or rapid neurological deterioration taking into account the possibility of interventional treatment.


Subject(s)
Carotid Artery, Internal, Dissection/diagnosis , Carotid Artery, Internal, Dissection/etiology , Craniocerebral Trauma/complications , Wounds, Nonpenetrating/complications , Accidents, Traffic , Adolescent , Brain Ischemia/etiology , Carotid Artery, Internal, Dissection/surgery , Fatal Outcome , Humans , Magnetic Resonance Imaging , Male , Tomography, X-Ray Computed
20.
J Neurosurg Sci ; 45(3): 127-39; discussion 140, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11731737

ABSTRACT

BACKGROUND: The results of the surgical resection of 9 clival tumors using the enlarged transcochlear approach (ETCA) are evaluated. The literature is reviewed to compare the ETCA with other approaches to the clival and petroclival region; the surgical indications are discussed. METHODS: Between June 1996 and June 1997, 9 patients were operated on through the ETCA either alone or combined with other approaches. Only meningiomas and chordomas with a significant involvement of the clivus and huge extension into the posterior fossa were included into this study. RESULTS: Gross total tumor removal was achieved in 5 cases and in 4 cases a residual meningioma was left in place inside the cavernous sinus and treated by radiosurgery. No postoperative mortality or major neurological morbidity were recorded. The postoperative facial nerve function was good in 75% of cases. No tumor recurrence was recorded (mean follow-up = 45.9 months). CONCLUSIONS: The indications to the ETCA should be as strict as possible. The ETCA is an effective procedure in the treatment of large clivopetrous tumors. Tumor characteristics like consistency, vascularity, encasements of vertebro-basilar vessels, bone erosion and previous surgery are also indicative. The transient postoperative facial nerve palsy and deafness should be considered as major disadvantages related to this approach.


Subject(s)
Chordoma/surgery , Meningeal Neoplasms/surgery , Meningioma/surgery , Neurosurgical Procedures , Skull Base Neoplasms/surgery , Adolescent , Adult , Aged , Child , Chordoma/diagnosis , Cochlea , Cranial Fossa, Posterior/pathology , Female , Humans , Male , Meningeal Neoplasms/diagnosis , Meningioma/diagnosis , Middle Aged , Neoplasm Invasiveness , Skull Base Neoplasms/diagnosis
SELECTION OF CITATIONS
SEARCH DETAIL